secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001213900-25-055402
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings: Phase 3 Trappsol Cyclo NPC1 study continues after DMC interim review
--------------------------------------------------------------------------------

- DMC recommends continuation of 96-week TransportNPC study after 48-week interim safety/efficacy analysis.
- Trappsol Cyclo well-tolerated; safety profile consistent with prior Phase 1/2 and open-label studies.
- FDA accepted statistical analysis plan for the TransportNPC study.
- Rafael closed $25M rights offering earlier June to support strategic objectives, including NPC program.
- Study is described as most comprehensive controlled pivotal study for NPC in patient size and global footprint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025055402/0001213900-25-055402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025055402/ea0246139-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer